Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Biophysical Assays

At Sygnature Discovery, we recognise that biophysics is a valuable component of drug discovery programs. We have invested in the establishment of scientific excellence and industry leading technology to grow our biophysics capability and to imbed the value of its use across our scientific teams.


Our biophysics platform provides techniques that can deliver hit finding approaches for fragment-based lead discovery and a full mechanistic, structural, kinetic, and thermodynamic profile for your novel compounds.

We have dedicated biophysicists who can support your integrated drug discovery program with a suite of high-end technology platforms that can deliver a complete biophysical assessment of your compounds of interest.

In addition to the range of in-house biophysics platforms, Sygnature has selected trusted strategic alliance partners to augment our biophysics capabilities, providing you with access to discovery excellence.

Biophysical Assays Services

Surface Plasmon Resonance (SPR)

Our biophysicists are proficient using state-of-the-art equipment to carry out label-free SPR assays, which measure compound, fragment or larger species (e.g., protein-protein) binding in real-time to generate accurate kinetic and binding mechanism information about a wide range of drug targets.


Fluorescent Thermal Shift Assays (FTSA)

We can deliver high-quality information on the thermal unfolding and stability of your protein target and effects of bound ligands using FTSA (or Differential Scanning Fluorimetry; DSF) that can help to further define your drug target’s binding mechanism of action.


Nuclear Magnetic Resonance (NMR)

Sygnature Discovery scientists have access to NMR instruments to facilitate the label-free description of compound, fragment and/or protein interactions and their integrity.


X-Ray Crystallography (XRC)

To generate a high-definition 3D structure of the binding site of hit or lead-like compounds on your drug target of interest, our bioscience team can facilitate the provision of this information through our strategic alliance partner Peak Proteins.


Cellular Thermal Shift Assay (CETSA®)

Our biophysicists can incorporate the use of the CETSA® platform into your integrated project via our alliance with Pelago Bioscience.


Isothermal Titration Calorimetry (ITC)

During lead identification, thermodynamic and kinetic profiling of drug targets is of key importance to give an enhanced insight into the binding mechanism of novel compounds. We can support research on your drug candidates by determining heat capacity changes, stoichiometry, and other parameters using ITC.


Microscale Thermophoresis (MST)

Our biophysicists can assess ligand binding interactions via effects of a precise thermal gradient on a molecule’s hydration shell or charge through this homogeneous assay solution based technology, which complements the findings obtainable through SPR.


Dynamic Light Scattering (DLS)

Our biophysicists can assess the aggregation behaviour of your compounds, targets and complexes within solution using DLS techniques. This can assist you in the characterization of lead compounds and in the development of drug delivery systems or biologic therapeutics.